Browsing Tag
Jakafi XR
1 post
Incyte (Nasdaq: INCY) Q2 2026 revenue jumps 38% as CMS Opzelura settlement lifts headline growth
Incyte Q2 revenue jumped 38% on a $246m CMS Opzelura benefit, but the underlying growth line and $1.27bn Vega charge redraw the 2026 investment case.